These immunolabelling patterns were representative of a large cohort of tissue samples from PCa patients (n > 100), which were previously used to validate these markers where there was a significant change in sortilin and syndecan-1 expression and distribution that enabled more reliable IHC-assisted grading and better stratification of patients12,18. The gene discussed is SDC1; the disease is posterior cortical atrophy.